IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.53
+7.54%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$28.73
From 52W high−32.10%
Volume2.66M
Market cap$6.31B
P/E (TTM)—
P/S (TTM)888.8x
Div yield—
Key dataNov 6, 2026
Open
$28.73
From 52W high
−32.10%
Volume
2.66M
Market cap
$6.31B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.2x
P/E (TTM)
—
RSI (14)
47.5
MomentumView details →
1D Return
+7.54%
YTD Return
+17.15%
SummaryUpdated Jun 1, 2026
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. The company went public in June 2019 and operates as a subsidiary of Roivant Sciences Ltd. Immunovant focuses on developing innovative monoclonal antibody treatments for autoimmune diseases, with its lead drug candidate batoclimab currently advancing through multiple Phase II clinical trials for various autoimmune conditions.
Similar companies
Latest newsMore news →
Immunovant announced that it will report financial results for the fiscal second quarter ended September 30, 2026, on November 9, 2026, before the market opens.18d agoKuehn Law, PLLC said it is investigating whether Immunovant officers and directors breached fiduciary duties to shareholders through potential self-dealing.26d ago